Treatment or Lack of Treatment of Small Renal Masses

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

Now Viewing

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

EP: 9.The ZIRCON Trial

EP: 10.The MOA of TLX250

EP: 11.Top-Line Results of the Phase 3 ZIRCON Study

EP: 12.Risk Stratification in ccRCC: The Impact in Patient Populations

Treatment Approaches and Role of Biopsy

Main Discussion Topics:

• Masses under 2 cm are typically managed with active surveillance.
• Options for masses that are 2 to 4 cm include ablation (eg, cryotherapy, radiofrequency ablation) and surgical approaches.
• Kidney cancer is often treated without tissue diagnosis, unlike most other cancers.
• Biopsy utilization depends on tumor characteristics and management implications.

Key Points for Physicians:

• Small masses (< 2cm) are generally appropriate for active surveillance.
• Approximately 60% to 70% of small renal masses are malignant.
• Biopsy is considered for unusual lesions, suspected metastases, or infiltrative patterns.
• Risk stratification can be enhanced by considering patient age, gender, and tumor size.

Notable Insights:

Kidney cancer remains one of the few cancers typically treated without tissue confirmation, though this approach is increasingly being questioned.

Clinical Significance:

Size-based management algorithms provide practical guidance, but patient-specific factors and tumor characteristics should inform individualized treatment decisions.